Please assess the completion status of the following clinical trial:

Trial Title: A Research Study to Look Into How Well Semaglutide Medicine Works at Different Doses in People With Type 2 Diabetes and Overweight

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: DOUBLE
- Phase: PHASE2
- Number of Arms: 6.0

Eligibility Criteria:
Inclusion Criteria:~* Male or female.~* Aged 18-64 years (both inclusive) at the time of signing informed consent.~* Diagnosed with type 2 diabetes mellitus greater than equal to (≥) 180 days prior to the day of screening.~* Glycosylated haemoglobin (HbA1c) of 7.0 - 10.5 percentage (%) \[53 - 91 millimoles per mole (mmol/mol)\] (both inclusive).~* Body Mass Index (BMI) ≥ 27.0 kilograms per meter square (kg/m\^2).~* Stable daily dose(s) ≥ 90 days prior to the day of screening of any metformin formulations.~Exclusion Criteria:~* Treatment with any medication for the indication of diabetes or obesity other than stated in the inclusion criteria within 90 days before screening. However, short term insulin treatment for a maximum of 14 days prior to the day of screening is allowed, as is prior insulin treatment for gestational diabetes.~* Uncontrolled and potentially unstable diabetic retinopathy or maculopathy. Verified by a fundus examination performed within the past 90 days prior to day of screening or in the period between screening and randomisation. Pharmacological pupil-dilation is a requirement unless using a digital fundus photography camera specified for non-dilated examination.~* Renal impairment measured as estimated glomerular filtration rate (eGFR) value of less than (\<) 30 milliliters per minute (mL/min)/1.73 meter square (m\^2) at screening.

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: 64 Years
- Healthy Volunteers: f

Study Arms:
- Semaglutide 2 mg (Type: EXPERIMENTAL): Participants will receive once-weekly semaglutide 2 mg subcutaneous (s.c.) injection.
- Semaglutide placebo 2 mg (Type: PLACEBO_COMPARATOR): Participants will receive once-weekly semaglutide placebo 2 mg s.c. injection.
- Semaglutide 8 mg (Type: EXPERIMENTAL): Participants will receive once-weekly semaglutide 8 mg s.c. injection.
- Semaglutide placebo 8 mg (Type: PLACEBO_COMPARATOR): Participants will receive once-weekly semaglutide placebo 8 mg s.c. injection.
- Semaglutide 16 mg (Type: EXPERIMENTAL): Participants will receive once-weekly semaglutide 16 mg s.c. injection.
- Semaglutide placebo 16 mg (Type: PLACEBO_COMPARATOR): Participants will receive once-weekly semaglutide placebo 16 mg s.c. injection.

Based on this trial design, predict the completion outcome and termination type (if applicable).